# Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

> **NCT02404051** · PHASE3 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 745 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Breast Cancer
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Locally Advanced Malignant Neoplasm

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02404051
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-01
- **Final completion:** 2019-01
- **Target enrollment:** 745 (ESTIMATED)
- **Last updated:** 2016-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404051, "Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02404051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*